Literature DB >> 25500996

Promoter-dependent activity on androgen receptor N-terminal domain mutations in androgen insensitivity syndrome.

Rieko Tadokoro-Cuccaro1, John Davies, Nigel P Mongan, Trevor Bunch, Rosalind S Brown, Laura Audi, Kate Watt, Iain J McEwan, Ieuan A Hughes.   

Abstract

Androgen receptor (AR) mutations are associated with androgen insensitivity syndrome (AIS). Missense mutations identified in the AR-N-terminal domain (AR-NTD) are rare, and clinical phenotypes are typically mild. We investigated 7 missense mutations and 2 insertion/deletions located in the AR-NTD. This study aimed to elucidate the pathogenic role of AR-NTD mutants in AIS and to use this knowledge to further define AR-NTD function. AR-NTD mutations (Q120E, A159T, G216R, N235K, G248V, L272F, and P380R) were introduced into AR-expression plasmids. Stably expressing cell lines were established for del57L and ins58L. Transactivation was measured using luciferase reporter constructs under the control of GRE and Pem promoters. Intrinsic fluorescence spectroscopy and partial proteolysis studies were performed for mutations which showed reduced activities by using a purified AR-AF1 protein. Pem-luciferase reporter activation was reduced for A159T, N235K, and G248V but not the GRE-luciferase reporter. Protein structure analysis detected no significant change in the AR-AF1 region for these mutations. Reduced cellular expression and transactivation activity were observed for ins58L. The mutations Q120E, G216R, L272F, P380R, and del57L showed small or no detectable changes in function. Thus, clinical and experimental analyses have identified novel AR-signalling defects associated with mutations in the structurally disordered AR-NTD domain in patients with AIS.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25500996     DOI: 10.1159/000369266

Source DB:  PubMed          Journal:  Sex Dev        ISSN: 1661-5425            Impact factor:   1.824


  4 in total

1.  Clinical characteristics, AR gene variants, and functional domains in 64 patients with androgen insensitivity syndrome.

Authors:  Q Liu; X Yin; P Li
Journal:  J Endocrinol Invest       Date:  2022-08-16       Impact factor: 5.467

Review 2.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

Review 3.  Comparing the rules of engagement of androgen and glucocorticoid receptors.

Authors:  Frank Claessens; Steven Joniau; Christine Helsen
Journal:  Cell Mol Life Sci       Date:  2017-02-06       Impact factor: 9.261

4.  Predicting puberty in partial androgen insensitivity syndrome: Use of clinical and functional androgen receptor indices.

Authors:  Ngee Lek; Rieko Tadokoro-Cuccaro; Jonathan B Whitchurch; Bismoy Mazumder; Harriet Miles; Philippa Prentice; Trevor Bunch; Karolina Zielińska; Veronika Metzler; Nigel P Mongan; David M Heery; Ieuan A Hughes
Journal:  EBioMedicine       Date:  2018-10-11       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.